Beacon Therapeutics Announces Closing of Oversubscribed Series C Financing for Over $75 Million

Contributed by: GlobeNewswire

Tags

Healthcare

More Like This

Beacon Therapeutics to Participate in TD Cowen's 46th Annual Health Care Conference

Beacon Therapeutics to Participate in the Jefferies Global Healthcare Conference

Beacon Therapeutics to Present at the 44th Annual JP Morgan Healthcare Conference

Beacon Therapeutics Annouces Presentations at the ARVO 2026 Annual Meeting

Beacon Therapeutics completes enrollment in registrational Phase 2/3 VISTA trial of laru-zova for patients with XLRP

Beacon Therapeutics completes enrollment in registrational Phase 2/3 VISTA trial of laru-zova for patients with XLRP

Beacon Therapeutics Announces Positive 12-Month Safety and Efficacy Update from Phase 2 DAWN Trial of laru-zova in Patients with X-linked Retinitis Pigmentosa (XLRP) at ARVO 2026 Annual Meeting

Beacon Therapeutics Announces Positive Phase 2 Interim 6-Month Data from DAWN Trial of Laru-zova in Patients with X-linked Retinitis Pigmentosa (XLRP) at ARVO 2025